Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-11-23 19:19 CET (UTC+1h)
 
Aga
Junior

US,
2017-09-06 13:52

Posting: # 17784
Views: 806
 

 syrup hybrid application [Regulatives / Guidelines]

Hi,
How could we proof equivalence for syrups, to authorise strength 5 mg/ml when only lower strength of reference product is available (2 mg/ml)? BEQ? In vitro?
The substance is present for more than half of a century on the market and efficacy for tablet (10 and 25 mg) and syrup lower strength (2 mg/ml) is documented in the literature.
best regards,
Aga
ElMaestro
Hero

Denmark,
2017-09-06 14:44

@ Aga
Posting: # 17786
Views: 681
 

 syrup hybrid application

Hi Aga,

» How could we proof equivalence for syrups, to authorise strength 5 mg/ml when only lower strength of reference product is available (2 mg/ml)? BEQ? In vitro?
» The substance is present for more than half of a century on the market and efficacy for tablet (10 and 25 mg) and syrup lower strength (2 mg/ml) is documented in the literature.

Since you use the term "hybrid" I assume you imply EU submission? If so, get a scientific advice at three agencies. You might well see that they perceive such a case completely differently among the various agencies; some might allow this as a bibliographical application, some might want you to go 10.3 and others yet may think this is something else. If you run into someone fresh out of university this could easily get impractical especially if the syrup is not a solution.

I could be wrong, but…


Best regards,
ElMaestro

No, I still don't believe much in the usefulness of IVIVCs for OIPs when it comes to picking candidate formulations for the next trial. This is not the same as saying I don't believe in IVIVCs.
Aga
Junior

US,
2017-09-07 13:52

@ ElMaestro
Posting: # 17791
Views: 612
 

 syrup hybrid application

Dear ElMaestro,

Thank you very much for your response. Yes, EU submission is considered and the aim of the project is to make posology more practical, as with the low strength the adult is consuming the whole package in less than 2 days.
If we would go 10.3 - how we should prove equivalence with this tricky syrup? Bioequivalence - because the product is not pharmaceutically equivalent? or can we somehow prove pharmaceutical equivalence with double dose vs single dose? Is it possible?

best regards,
Aga
ElMaestro
Hero

Denmark,
2017-09-07 14:10

@ Aga
Posting: # 17792
Views: 605
 

 syrup hybrid application

Dear Aga,

» If we would go 10.3 - how we should prove equivalence with this tricky syrup? Bioequivalence - because the product is not pharmaceutically equivalent? or can we somehow prove pharmaceutical equivalence with double dose vs single dose? Is it possible?

I really meant what I said - this can be perceived completely heterogeneously between countries. You may get as many answers as there are agencies. Therefore, take scientific advices (pl.) and try to rely on that. They may need in vivo studies, or they may not. They may need ther. equivalence in stead of bioequivalence, or they may not. They may let you get away with some in vitro work, or they may not. They may accept a bunch of literature, or they may not. They may be totally paranoid and conservative because you are doing something related to children, or they may not.
Request scientific advice. Even if there is no budget and no time.:-)

Note also that BE does not have the same definition in EU and US.

I could be wrong, but…


Best regards,
ElMaestro

No, I still don't believe much in the usefulness of IVIVCs for OIPs when it comes to picking candidate formulations for the next trial. This is not the same as saying I don't believe in IVIVCs.
Aga
Junior

US,
2017-09-07 14:54

@ ElMaestro
Posting: # 17793
Views: 606
 

 syrup hybrid application

Dear ElMaestro,

Thank you so much for advice.
Surely we are going to ask Agency, we already contacted one.

» Note also that BE does not have the same definition in EU and US.

I didn't know that:)

best regards,
Aga
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum | Admin contact
17,494 Posts in 3,746 Threads, 1,090 registered users;
30 users online (0 registered, 30 guests).

Cave diving is like playing chess
but the king is not made of wood.    Jochen Hasenmayer

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed